Report of the National Consensus Conference on Safety of Organs and Tissues for Transplantation
LET YOUR COMPUTER DO THE SEARCHING!

...Need to know how to market a new drug in Canada?
...Want information on the drug regulatory process?
...Need to know what the newest drugs on the Canadian market are?
...Want direct access to our forms and policies?
...Need to know the requirements for labelling drugs?
...Want to receive an electronic version of the Canadian Drug Identification Code Book and perform your own searches?

All this and more on the Drugs Directorate is available right now on the BBS.
Instant access via Internet: hpb1.hwc.ca port 7300 (Gopher) or http://www.hwc.ca:8300 (World Wide Web)
For a free startup kit for modem users please send a fax to the Drugs Directorate BBS Manager (613) 941-0825.
Be sure to include your full mailing address.

Aussi disponible en français sous le titre

*Rapport de la Conférence consensuelle nationale sur la sécurité des organes et des tissus destinés aux greffes*

© Minister of Supply and Services Canada 1995
Cat H49-102/1995E

January 1996

I am pleased to forward to you the Report of the National Consensus Conference on Safety of Organs and Tissues for Transplantation. The meeting was sponsored by the Drugs Directorate and was held in Ottawa from October 29 to 31, 1995. This conference was successful in achieving a general consensus on the proposed Canadian General Standard on Safety of Organs and Tissues for Transplantation and in recommending a risk-management framework for compliance and oversight.

I wish to acknowledge the contribution of my co-chair, Dr. Calvin Stiller, of the expert advisors and of the organizing committee for their efforts in planning this meeting. Also acknowledged are the efforts of workshop chairs and rapporteurs, of special guest speakers from Australia, Europe and the United States, and of all invited participants from across Canada.

Special thanks also go to Dr. Keith Bailey and Dr. Wilbert Keon for their successful efforts to facilitate the consensus-building process.

Respectfully yours,

May S.M. Smith MD
Conference Co-chair and
Chair of the Organizing Committee
Executive Summary

To facilitate a consultative approach to addressing the potential risk of disease transmission through organs and tissues in transplantation, the National Consensus Conference on Safety of Organs and Tissues for Transplantation was held in Ottawa from October 29 to 31, 1995.

The goal of the conference was to reach agreement on methods to reduce the risks of disease transmission by organs and tissues intended for transplantation.

The objectives of the conference included obtaining expert guidance on the proposed Canadian General Standard on Safety of Organs and Tissues for Transplantation and proposing a risk-management framework for oversight and compliance to ensure safety.

The conference was attended by 65 invited participants, who represented a broad spectrum of expertise in fields related to organ and tissue transplantation. Invited speakers from the U.S. Food and Drug Administration (Center for Biologics Evaluation and Research), the Eurotransplant Foundation, and the Australian Therapeutic Goods Administration provided an international perspective.

Conference participants were given background documents that included the proposed Canadian General Standard on Safety of Organs and Tissues for Transplantation, a report entitled Safety of Organ and Tissue Transplantation in Canada, and a paper, Principles of Risk Management.

Achievements

! The conference was successful in bringing together a broad range of experts in the field of transplantation and in achieving a consensus.
! The proposed Canadian General Standard on Safety of Organs and Tissues for Transplantation was accepted in principle.
! A risk-management/regulatory framework was proposed (see Figure 1, page 5).


Recommendations

The conference resulted in the following recommendations being made to Health Canada’s Drugs Directorate:

! that the proposed Canadian General Standard on Safety of Organs and Tissues for Transplantation be revised to incorporate input from experts at the conference;

! that the revised Canadian General Standard on Safety of Organs and Tissues for Transplantation be accepted as a template for the development of subsets of specific standards for individual organ and tissue types; and

! that the risk-management/regulatory framework proposed by the participants at the conference be adopted for implementation by the Drugs Directorate.

Next Steps

The conference report will be widely distributed for information and comment. The proposed risk-management/regulatory framework will be carefully reviewed and considered by the Drugs Directorate.
Figure 1
Proposed Risk-Management/Regulatory Framework

General Standard

**Standard Template:** Serology Testing, Donor-screening, Record-keeping, Labelling, Packaging, Reporting

**Organ/Tissue-specific Subsets:** Solid Organs, Ocular Tissues, Reproductive Tissues, Muscular-Skeletal/Heart Valves/Skin, Bone Marrow/Stem Cells

Regulatory
Drugs Program
Inspection and Audit

Expert Advisory Committee/Coalition

Accreditation
CCHSA*
CHA*

Registry/Databases (CORR*)
- Tracking
- Specific Donor/Recipient Information
- Complications and Adverse Reactions

* Suggested third-party associations
CCHSA Canadian Council for Health Services Accreditation
CHA Canadian Hospital Association
CORR Canadian Organ Replacement Register
# Table of Contents

**Introduction** .................................................................................. 7  
Opening Remarks ........................................................................... 7  
Goal and Objectives of the Conference ........................................... 9  
Overview of Transplantation in Canada ........................................... 10

**Conference Proceedings** ............................................................ 12  
General Plenary Session ................................................................ 12  
Risk Assessment and Management .................................................. 12  
International Perspectives .............................................................. 14  
Workshop ...................................................................................... 16  
Organ-specific and Tissue-specific ................................................. 16  
Theme-specific ............................................................................. 25  
Oversight and Compliance .............................................................. 32  
Plenary Session ............................................................................ 32  
Discussion .................................................................................... 36  
Summary ...................................................................................... 38

**Closing Remarks** ........................................................................ 39

**Directory of Organizers and Participants** ................................. 40
Introduction

Opening Remarks
Mr. Dann Michols, Director General, Drugs Directorate

The mission of the Drugs Directorate is to strive to assure that drugs available in Canada are safe, effective, and of high quality by doing the following:

- effectively, efficiently and continually assessing the benefits and risks of drugs;
- managing the risks appropriately; and
- developing and disseminating information that encourages the optimal use of drugs.

At the moment, tissues and organs are considered drugs and, therefore, fall within the Drugs Directorate’s mandate for regulation. The definition of “drug” in the Food and Drugs Act includes a substance or mixture of substances sold, manufactured or represented for use in the diagnosis, treatment, mitigation or prevention of disease, disorder or abnormal physical state, or the symptoms thereof, in humans or animals.

Tissues and organs fit into this definition well. Furthermore, a government decision in 1989 to define blood and blood components as drugs confirms this logical path. The Drugs Directorate is also developing sperm regulations under the act. Tissues and organs may follow similar regulatory reasoning. Concerns have arisen worldwide regarding the potential risk of disease transmission through blood, human tissues and organs. Public interest in Canada has increased as a result of the work of the Royal Commission on New Reproductive Technology and of the Krever Commission. If there is one thing we should learn from the unfortunate events being examined by Justice Krever, it is that if the human mind can ask the question, "Is there a risk?", then it ought immediately to take steps to determine how to mitigate that risk.

The Drugs Directorate believes that there is a potential risk associated with organs and tissues in transplantation and that this risk can best be assessed and managed by applying concepts such as those used in the management of drug risks and benefits. It is this belief that will be explored at this conference.

The regulatory process should be designed to ensure there is sufficient information generated throughout the process to enable effective, timely decisions concerning an intervention and its rational use. It should be designed to efficiently develop knowledge and information and make it available in a timely fashion to all decision-makers. It should also recognize the concept of shared responsibility. Other parties involved – the provinces, health professionals, researchers, industry and the public – each have a responsibility. A constructive regulatory framework defines the responsibilities of each partner to facilitate the free flow of information for informed decision-making. This conference will help identify these decision-makers and advise on their respective responsibilities.
While it continually reviews and learns from the experiences and best practices of other systems, the Canadian regulatory system is designed to meet the needs of Canadians within the context of the Canadian health system, the Canadian way of practising medicine and Canadian values. This expert group is being asked to apply this model as it addresses the challenge of regulating organs and tissues for transplantation.
Goal and Objectives of the Conference
Dr. May Smith, Conference Co-chair

The following are the goal and objectives as presented to the participants prior to the conference.

Goal

- to reach agreement on methods to reduce disease transmission by organs and tissues used in transplantation

Objectives

- to provide a forum to address risk-management and regulatory options;
- to reach agreement on the principal elements to be included in a set of generic national safety standards for donor-screening, serological testing, record-keeping, packaging and labelling, storage, and distribution;
- to reach consensus on mechanisms to ensure compliance with national standards; and
- to reach agreement on a national system for recording organ and tissue transplants to facilitate the follow-up of adverse events.

Background and Format

The conference will provide participants with appropriate background knowledge on the risks in transplantation, risk-assessment and management tools, and international experiences and approaches to ensuring the safety of organs and tissues for transplantation. Background documentation includes the proposed *Canadian General Standard on Safety of Organs and Tissues for Transplantation*. Organ-specific, tissue-specific and theme-specific workshops have been designed for participants to review the proposal and reach agreement on the principal elements of a generic standard.

Presentations and discussion will take place on possible mechanisms to ensure compliance with national standards. This will facilitate consensus-building in the development of recommendations for a risk-management/regulatory framework to ensure safety and compliance.

A report of recommendations made at this meeting will be widely distributed for information and comments.

*Note:* A directory of participants and organizers is attached.
Overview of Transplantation in Canada
Dr. Calvin Stiller, Conference Co-Chair

Transplantation in Canada has had an illustrious history. The first era of transplantation started in 1963 with kidney transplantation in Montreal. These were the post-Barnard, pre-cyclosporin-suppression times, when expectations far exceeded what could be delivered. Then in the 1980s, cyclosporin ushered in T-cell immune-suppressive therapy and the second era of transplantation. This new era also witnessed the initiation and paralleled success of cell and tissue transplantation. Canada notably excelled in both application and outcomes.

Transplantation was established on a centre-by-centre basis, with no national vision of what it could or should be. Transplantation developed to address a bedside need and as a life-saving means. Once established as possible, patients got out of hospital and onto the front pages of the newspaper: transplantation became a \textit{de facto} reality.

This second phase involved establishing credibility and confidence in our work. Outcomes had to be superior to those of other centres. This resulted in the establishment of "risk" categories for donor and recipient pools. During these "risk-aversive" times, donors exceeded the number of recipients. But, as confidence in the outcomes improved, so did the waiting list and referrals of patients who were just outside the limits of the low-risk, good-outcome criteria that had been established.

This was an entrepreneurial phase. Rapid development, no preclinical testing and "ad hockery" were the rule. Common direction and standardization were limited because of competition among centres, with these centres all being at different levels of development. Regional user groups were established based on a need to demonstrate equitable distribution of organs. Each centre was expected to apply safety standards, but no national body was established to ensure that this was done. Tissue-typing became a surrogate for co-operation and sharing of standards. Algorithms were devised to assure the equal distribution of organs. Rudimentary audits, conducted irregularly after the fact, were used to police the application of the algorithms.

The record of Canadian transplantation in this "wild west" era has been quite remarkable. We led the western world in graft and patient survival. We are near the top in terms of the number of donors and transplants per million population. Canada has been a pioneer in lung, small bowel, heart-lung and neural tissue transplantation. Clinical research with new immunosuppressive therapies and implantable parts as a bridge to transplant are also to our credit. Canada is also a leader in the study and application of ethics in transplantation. This is an enviable record in an unorganized era that has depended so much on individual integrity.

Competence is an obvious key to the successes we have experienced. But without trust from all stakeholders, this success cannot be sustained. Trust is the key – for institutions, government and patients, both recipients and donors. Trust is based on integrity combined with expertise and knowledge. While scientific publications and registries of outcomes are essential, a transparent process of audit is both necessary and demanding.
We are now entering the third era of transplantation in Canada. This era centres on the issues of this conference. Effective solutions to the issue of safety will allow us to take advantage of future technological changes.

New immune-suppressive agents, resulting in a more immune-tolerant host, expansion of the pheno-types of donors, and manipulation of donor-derived cells *in vitro* to modify the rejection process (as with combined marrow/solid-organ transplants) are examples of future options available and ones that will mean that safety issues will become even more pertinent to transplantation. The use of organs from non-perfusable donors will shorten the time of predonation observation and will emphasize the surveillance that we need to put into place both locally and nationally.

How do we maintain the trust that Canadians have placed in us? How do we continue our enviable record? How do we adapt to the extraordinary changes that face us? It is our view that we must have a framework for safety and risk management. We deliver life, either enhanced or extended, to our recipients. But we must do so at the least risk that is compatible with these extraordinary circumstances and with the full knowledge of that risk.

The background work has been done. The individuals in this group represent the key players and expertise necessary. Our patients, our colleagues and our nation reasonably expect us to propose the elements to be contained in a set of national safety standards, to achieve a consensus on methods of verification and, having devised these outlines, to propose the skeleton of a simple workable system.
Conference Proceedings

General Plenary Session – Risk Assessment and Management

Report on Risk Assessment
Dr. Paul Greig

The transplantation of human organs (heart, lung, liver, kidney, pancreas and intestine) and tissues (cornea, heart valve, bone, bone products, dura, fascia, skin, reproductive tissues, bone marrow and stem cells) is a common activity in Canada. The transplantation of these organs and tissues is expected to increase, but is currently limited by the critical shortage of donated organs and by further advances in technology, which are anticipated to improve the results of transplantation and expand the potential for this therapy.

Transplantation of this wide variety of organs and tissues has many features that deserve national consideration. One of these is the safety of the process. There are risks associated with every medical/surgical activity; however, transplantation brings a number of unique risks. These include those associated with donor maintenance, donor-screening, organ allocation, organ retrieval, organ storage and transplantation, organ implantation, rejection, adverse effects of immune-suppressive or other drugs, and the risk of the transmission of disease from the donor to the recipient.

Transplantation of organs and tissues as performed in hospitals and clinics throughout Canada is considered to be exemplary. The results that are reported are equivalent to those reported by the national transplantation organizations in other countries. There is, however, no national organization in Canada to establish and maintain standards of practice, enforce these standards, ensure equitable organ allocation through sharing, promote organ and tissue donation, audit and report the results of transplantation, investigate and manage transplant-related problems, and ensure that transplantation is performed to the highest technical and ethical standards.

To begin to address the need for national standards for organ and tissue transplantation, Health Canada's Bureau of Biologics approached Organ Sharing Canada (OSC – a joint initiative of the Canadian Transplantation Society and the Canadian Association for Transplantation, which was launched in 1992 to establish national equity in transplantation through organ-sharing and standards) to produce a working document that addresses the risks and current standards and practices of transplantation in Canada. In October 1994, OSC organized a working group of transplant professionals from across Canada who researched and authored a document entitled The Safety of Organ and Tissue Transplantation in Canada, which was delivered to the Bureau of Biologics in December 1994. This document, a copy of which was provided in the preregistration package for this conference, details Canadian transplantation activity, potential risks associated with transplantation, the incidence of occurrence of these risks in Canada, when known or documented, current standards of practice, and a proposal for establishing, maintaining and enforcing national standards.
The speaker reviewed the findings of the working group as a starting point for the National Consensus Conference on Safety of Organs and Tissues for Transplantation.

**Principles of Risk Management**  
**Mr. Dave Blaker**

From the risk-management-systems perspective, there are a number of essential elements that must be included in the development and operation of a risk-management process.

In considering the various risk-management options, the following questions must be addressed:
- What are the pros and cons of each option?
- Is there a thorough, clear understanding of the workings of the option?
- What are the costs and consequences of selecting the option?
- Can the option be enforced?
- What is the likelihood of compliance with the option?
- Does the option provide timely resolution of problems?
- Can the effect of the option be tracked and evaluated?

Once the risk-management option is put in place, it must contain a process for increasing the understanding of the actual risks of disease transmission via tissues and organs. The risk-management option must be capable of reacting to new hazards and to new risk estimates.
General Plenary Session – International Perspectives

**U.S. Approach to Assuring the Safety of Human Organs and Tissues for Transplantation**

*Dr. Thomas Arrowsmith-Lowe*

Regulatory responsibility for human organs and for human tissues intended for transplantation in the United States resides in the Health Resource and Service Administration (HRSA) and the Food and Drug Administration (FDA), respectively. These two agencies of the U.S. Public Health Service have slightly differing approaches to regulation. HRSA focuses primarily on the availability of organs for transplantation. In response to a disparity between the number of organs available for transplantation and the number of patients requiring transplantation, HRSA strives to increase the number of donors and to match donors with recipients. FDA focuses its efforts on enforcing a federal regulation that requires that tissue available for transplantation is from donors who were adequately screened and tested for HIV and Hepatitis. Many of the organizations that procure organs in the U.S. also procure tissue for transplantation. The lack of a single donor-screening approach for both organs and tissues has the potential to be problematic.

The speaker discussed the approach to donor-screening that the FDA is recommending for human-tissue donors, related this approach to the recommendation on organ and tissue transplantation made by the Centers for Disease Control, and explored the feasibility of such an approach being employed for donors who provide both organs and tissue for transplantation.

**The Australian Regulatory Approach: Organs and Tissues for Transplantation**

*Ms. Carolyn Woodruff*

Tissues for transplantation have been regulated under the *Therapeutic Goods Act, 1989*. Prior to that date, tissues and organs for transplantation were regulated only under state or territory legislation, which was concerned with such factors as consent, payment (none allowed) and medical determinations of death.

The national legislation regulates therapeutic goods through premarket evaluation, postmarket surveillance and licensing of manufacturers. With respect to tissues, those that have not undergone any alteration in physical, mechanical or biological properties are regulated solely on the basis of the evaluation and licensing of the tissue-banking facilities.

In the last two years, a code of good-manufacturing practice for tissue banks has been drawn up. This code sets out the minimum requirements of a quality system for tissue banks. It is intended that the style of the code should not restrict innovation in tissue-banking practice, nor should it inhibit the use of new, as yet non-commercial, tests for infectious agents.
Current Regulation and Practices in Europe
Dr. Huibert A. Tjabbes

In the field of transplantation, cooperation in the European Union is not yet very extensive. In most countries, no formal regulation concerning safety exists and the field has had to organize itself. Each organization has developed its own method for achieving safety. Tissue-banking organizations in general are more strict in their screening than organ-exchange organizations.

At the European level, there are some initiatives: voluntary guidelines have been published by tissue-banking associations; the Council of Europe is preparing voluntary guidelines on serological testing; and the European Commission published a report stressing the importance of European regulation. Regulation at the European level will, however, take a long time, and it is not yet clear if all forms of transplantation will be regulated the same way.

Note: Copies of overheads from the presentations are available upon request. Please contact Dr. May Smith, Bureau of Biologics, Drugs Directorate – tel.: (613) 952-0237, fax: (613) 941-5481.
Workshops – Organ-specific and Tissue-specific

Summary of Organ-specific and Tissue-specific Workshops
Dr. May Smith

Participants in each organ-specific and tissue-specific workshop were asked to discuss all of the questions listed below, and to present their deliberations under the following headings: Areas of Consensus and Unresolved Issues. (Note that a general summary of the organ-specific and tissue-specific workshops is possible because each workshop addressed the same questions. The theme-specific workshops addressed area-specific questions and their findings are presented separately.)

Question 1: What are the specific risks in this organ/tissue group (i.e. Which are the transmittable diseases specific to this group of tissues?)?

General consensus was reached on the transmittable diseases as listed in the Canadian General Standard with a few additions.

Question 2: What are the standards to be followed nationally?

Some special guidelines and/or standards specific to each group, and other examples of serological testing and screening, should be included in the generic standards.

Question 3: Is the proposed Canadian General Standard acceptable?

All groups agreed that the Canadian General Standard was acceptable in principle as a template.

Question 4: In the context of risk management, are there any specific additional criteria or exceptions to this standard for a specific organ or tissue group?

Consensus was reached that risk-management issues are identifiable and should be included in the Canadian General Standard (i.e. experience and training of medical directors), and that standards should apply to end users as well. Moreover, standards should include disease-transmission risk to medical personnel.

Question 5: Can the proposed standard and future standards be applied retroactively to all banked tissues?

The consensus was that, when possible, appropriate or feasible, the archiving of sera is recommended. The issues here tend to centre on problems of logistics and limited resources.

Question 6: Which risks does your group wish to see audited or tracked?

Consensus was reached that receiving feedback on recipient information, infection, complications and diseases, as well as genetic information, was desirable for tracking and auditing. There is consensus that the proposed Canadian General Standard on Safety of Organs and Tissues for Transplantation is acceptable as a template for developing and refining specific standards relevant to each organ and tissue group. There is a need, though, to define absolute and
relative screening criteria for each group. All groups agree that auditing and tracking of disease and infection is essential to ensuring safety.

**Solid Organs**

**Chair: Dr. Wilbert Keon**  
**Rapporteur: Mrs. Gail Werner**

**Areas of Consensus**

1. Risks to solid organs are viral, bacterial, fungal, malignancy, genetic, high-risk screening, past and current medical history and organ function.

2. Tests: HIV 1/2, HTLV 1/2, Hepatitis B (Surface Antigen and Core Antibody), Hepatitis C, Syphilis, CMV and EBV (Toxoplasmosis at program's discretion).

3. History: documented past and present history, cancer and disease – each case must be assessed according to CDC guidelines, but HIV-positive recipients must not be rejected on the basis of them. Physical exam, lab tests, operative findings post mortem.

4. The only absolute contraindication is cancer in the specific organ. All other contraindications are relative.

5. Assess all as potential donors.

6. Proposed standards need extensive revision, especially contraindications for donation.

   Organs cannot be banked or quarantined. Serum is, in most cases, already banked or quarantined, and could be tested retrospectively for newly identified organisms. Quarantine to minimize risk does not work for this category, given the time-related constraints associated with solid-organ transplantation.

**Tracking**

- use of organs from any donor with relative contraindications in relation to outcome;
- any development of cancer in recipients; and
- any development of transmittable or infectious disease especially Hepatitis B, Hepatitis C, EBV and HIV.

**Unresolved Issues**

The following issues from the proposed *Canadian General Standard on Safety of Organs and Tissues for Transplantation* were raised but not resolved.
<table>
<thead>
<tr>
<th>Pg</th>
<th>Proposed Standard</th>
<th>Comment or Suggested Revisions</th>
</tr>
</thead>
<tbody>
<tr>
<td>11</td>
<td>All donor, processing, storage and distribution records must be maintained indefinitely.</td>
<td>Concern about feasibility.</td>
</tr>
<tr>
<td>12</td>
<td>Hepatitis B vaccination shall be offered free of charge to all non-immune personnel whose job-related responsibilities involve the potential exposure...</td>
<td>The organ procurement organization shall be responsible for ensuring appropriate vaccination be offered to all non-immune personnel whose job-related responsibilities involve the potential exposure...</td>
</tr>
<tr>
<td>13</td>
<td>Informed consent includes notification of all possible risks, harms and tests to be performed.</td>
<td>Informed consent includes notification of all reasonable risks, harms, tests to be performed.</td>
</tr>
<tr>
<td>13</td>
<td>...requirement for virological testing, especially HIV and HBsAG.</td>
<td>...requirement for virological testing, especially HIV, HBsAG and HCV.</td>
</tr>
<tr>
<td>13</td>
<td>Procurement from living persons incompetent to consent should be limited to donors and recipients of the same family and involve an independent third party (i.e. court or review board).</td>
<td>Delete. Dealt with legally on a provincial basis.</td>
</tr>
<tr>
<td>14</td>
<td>...except for reimbursement of costs directly associated with the donation, including compensation for the donor's time.</td>
<td>Delete: including compensation for the donor's time.</td>
</tr>
<tr>
<td>15</td>
<td>Donor Age – Donor age criteria for each kind of donation shall be established and documented.</td>
<td>Delete</td>
</tr>
<tr>
<td>15</td>
<td>CONTRAINDICATIONS</td>
<td>ADD (Absolute) 1) Those donors who may have a malignancy that is transmissible by tissues or organs. 2) HIV-positive donor when the tissue or organ is to be transplanted into an HIV-positive recipient.</td>
</tr>
<tr>
<td>16</td>
<td>...presence or clinical suspicion of neurologic degenerative disease or dementia (such as Alzheimer's or multiple sclerosis).</td>
<td>...presence or clinical suspicion of multiple sclerosis.</td>
</tr>
<tr>
<td>16</td>
<td>...congenital rubella ...Reye's syndrome</td>
<td>...presence or clinical suspicion of genetic disease that is transmissible.</td>
</tr>
<tr>
<td>16</td>
<td>...active septicemia (bacteremia, fungemia, viremia) ...active disseminated lymphomas</td>
<td>...untreated systemic infection.</td>
</tr>
<tr>
<td>16</td>
<td>HIV-seropositive donors</td>
<td>HIV-seropositive donors, unless recipient is HIV-positive.</td>
</tr>
<tr>
<td>16-17</td>
<td>...persons with repeatedly reactive screening</td>
<td>CDC Guidelines — if recipient is HIV-positive.</td>
</tr>
<tr>
<td>17</td>
<td>Screening tests that have complied with Canadian regulations for certain viruses shall be performed on donor blood.</td>
<td>Screening tests that have complied with Canadian regulations for certain infectious agents shall be performed on donor blood.</td>
</tr>
<tr>
<td>18</td>
<td>For cadaveric donors, the donor's physician and/or the physician who signed the death certificate must be notified.</td>
<td>Should the family of the cadaveric donor be notified?</td>
</tr>
<tr>
<td>19</td>
<td>HTLV-I and HTLV-II screening is not required.</td>
<td>HTLV-I and HTLV-II screening is required.</td>
</tr>
</tbody>
</table>
In case of immunosuppressed recipients, cytomegalovirus (CMV) testing should be performed. In case of immunosuppressed recipients, cytomegalovirus (CMV) and EBV testing should be performed.

**AUTOLOGOUS DONORS**

Delete

Maximum storage periods should be established for each organ or tissue. Maximum recommended storage periods should be established for each organ or tissue.
Ocular Tissues
Chair: Dr. Paul Dubord
Rapporteur: Mr. André La Prairie

Areas of Consensus

Note: There is a real shortage of tissues, especially corneal tissue, so restrictions cannot be tightened until there is sufficient tissue to meet requirements.

1. It was agreed that the specific risks identified in the proposed standard were acceptable for ocular tissues, with some modifications for diseases such as neoplasms, which are not contraindications for ocular tissue transplantations. There are almost no diseases, including Syphilis, that have an effect on ocular tissue that would qualify as a contraindication.

2. The Eye Bank Association of America produces the oldest and most internationally recognized standard for ocular tissues. It was agreed that this standard was a good reference document, but that there was merit in also having a Canadian standard.

3. The proposed standard is acceptable as a framework from which to work. It holds many advantages for the Canadian system. The proposed standard should be a document that responds to current scientific knowledge.

4. Risk should include the possibility of disease transmission to retrieval personnel. Appropriate tests for screening using post-mortem blood samples should be addressed.

5. Retroactivity is not an issue for eye transplantation (donors are dead). Storage of sera is not necessary for non-banked tissue.

6. Auditing and tracking should be compulsory with non-compliance penalties for both the bank and surgeon. Outcome analysis is key to determining the risks of tissue transplantation. Accreditation by knowledgeable and neutral parties is ideal.

Unresolved Issues

It was raised that the safety standard must be developed by an appropriate agency from which the standard operating procedures are generated. Still to be better defined is the role and expertise of the medical director.
Reproductive Tissues
Chair: Dr. John Jarrell
Rapporteur: Dr. Robert Casper

Areas of Consensus

Fresh semen should not be used under any circumstances (although the practice is happening in some places in Canada).

1. three tissues (sperm, oocytes, embryos) need to be handled individually
   - greater burden on reproductive technology to provide stringent screening because of life-enhancing quality of treatment in healthy patients
   - universal precautions for handling all samples
   - six-month quarantine adequate for HIV
   - HIV-positive samples can be handled and stored for cancer patients
   - take culture from the donor, not semen, for gonorrhea and chlamydia
   - no screening needed for ureaplasma

2. Only the current standards – the Canadian Fertility and Andrology Society ( Therapeutic Donor Insemination) Standards, 1992-93 – are acceptable.

3. - proposed Canadian General Standard is acceptable
   - compensation of donors is appropriate
   - personnel with serious infection (e.g. HIV-positive) should not be excluded from handling or storing samples. This section should be removed from the Canadian General Standard.
   - section on incompetent donors should be removed

4. - organ-specific experience and training requirements should be listed for medical directors
   - standards of practice should be followed by all end users of donor sperm
   - documentation of donor information should be provided if possible (donors do not have to be anonymous)

5. It is unlikely that future standards can be applied retroactively to currently banked samples, but one possible solution is to begin drawing a serum sample from all donors at the time of banking for freezing and future testing if new technology is available.
6. - expand follow-up past-pregnancy testing to include genetic, infection and efficacy issues  
- also follow recipient-related diseases such as ovarian cancer

Unresolved Issues

Is good medical/genetic history going back three generations as good as karyotyping? **Vote:** four in favour of routine karyotyping of donors, three against.

There is no efficient method of freezing oocytes, therefore, should oocyte donation be stopped because of the problem with HIV-screening? **Vote:** two in favour of not allowing oocyte donation, four against terminating oocyte donation.
Muscular-Skeletal/Heart Valves/Skin (Non-Perfused Tissues)
Chair: Dr. Michael Gross
Rapporteur: Dr. David Howarth

Areas of Consensus

Mission statement: require national standards with guidelines to carry into the future to minimize the risk to recipients.

Risks (* = absolute exclusion criteria)

1. * HIV 1/2, HBsAG, anti-HCV, HTLV-I/II, VDRL-positive (serology)
2. * Donor history
   - Jacob-Creutzfeldt, Rabies (i.e. potentially transmittable neurologic disease)
   - Malignancy – metastases, Haematologic (selected with respect to tissue, i.e., skin. Heart valves not affected)
   - * Infection as per p. 16
   - * CDC exclusionary criteria – require a uniform donor history for organs and tissues with respect to the following:
     1) lifestyle – drugs, sexual activity, institution (e.g. jail, prison more than 72 hours within the past 12 months) or psychiatric facilities; travel history; body piercing in non-sterile conditions in past 12 months; industrial-chemical exposure (lead, pesticides, arsenic, mercury or defoliants); rape in past 12 months; and
     2) previous medical care – medical history; human-pituitary-derived growth hormone; previous transplant recipient; and auto-immune diseases – consensus agreement with p. 15, 16, 17 and CDC exclusionary criteria for donor screening.

There should be retroactive donor history guidelines (for relative contraindications). Serologic tests must be done retroactively, and sera must be stored.

Tissue from living donors should be quarantined for 180 days (may be fewer with newer screens, e.g. PCR-DNA for HIV). Living donors: must have informed consent; patients testing positively must be informed; adverse reactions must be reported to the tissue bank (e.g. infection or failure of tissue), but not tracking of all patients (logistically impossible).

There must be standard appropriate clinical follow-up by the implant surgeon with respect to the efficacy of tissue.

Unresolved Issues

3. Is the proposed General Canadian Standard acceptable? It is felt that this standard is an overview that requires more specificity with respect to individual tissue types and organs.
   - examination of lymph nodes from donor (with respect to granulomas, e.g., TB, mets, lymphomas) and blood cultures, bone swab cultures – primary malignant brain tumours should be excluded?
Bone Marrow, Stem Cells (Haematopoietic Cell Transplantation)
Chair: Dr. Hans Messner
Rapporteurs: Dr. Anthony Ridgway and Dr. Armand Keating

Areas of Consensus

Current Status: Canadian transplanters have been actively involved in North American and international organizations to develop standards and guidelines for the practice of bone marrow transplant (BMT), and the procurement, processing, evaluation and administration of the graft. A draft document covering these issues was prepared by the Foundation for the Accreditation of Haematopoietic Cell Therapy (FAHCT).

1. Testing of the donor or graft for specific diseases: HIV 1/2, HTLV 1/2, Hepatitis B, Hepatitis C, CMV, Syphilis.

2. Current Canadian standards: none currently in use. Most transplant centres follow transfusion-practice guidelines as a minimum. Consensus was reached that the final FAHCT document will serve as a draft for Canadian guidelines and standards.

3. Canadian General Standard is acceptable with the following exceptions:
   a) donor selection: Consent re minors for cord-blood ownership – definition of family to include extended family; list of contraindications to donor selection requires revision to accommodate risk-benefit considerations; procurement/processing – pooling issues need to be addressed in the context of transfusion practice (e.g. pooled platelets); quarantine: not applicable because of need for timeliness of BMT; and
   b) adverse reactions: Reporting of transmissible reportable infections from the laboratory director to the transplant program director and to the appropriate provincial authorities and reporting of established infections arising from the graft by the BMT program director to the laboratory director and, when applicable, to the provincial health ministry. Lists of reportable infections should be forwarded to LCDC for national compilation. Reporting of adverse events should exclude expected BMT-related complications such as Graft Versus Host Disease.

4) Risk Management – quarantine is not applicable (see above). Issues related to graft manipulation are not addressed and should be addressed further elsewhere.

5) Retroactive applicability of banked cells – this is neither applicable to autografts nor possible with allografts since, in the latter, cells are almost never banked, with the exception of cord-blood cells.

6) Tracking and Auditing – graft-related infectious complications, graft effectiveness and development of graft-related genetic diseases should all be tracked and audited.
Workshops – Theme-specific

Serology Testing
Chair: Dr. David Howarth
Rapporteur: Dr. John Spika

1. For what infections should organ and tissue donors be screened?

1.1 Given that the Health Protection Branch, Bureau of Biologics, makes risk-benefit assessment necessary for serological tests for blood donors, should testing requirements for organ/tissue donors be the same as those for blood donors? What are the reasons for and against such requirements?

With the exception of ocular tissues, serologic tests currently recommended for blood donors should also be used for the donors of these tissues; however, the result of a VDRL test is not required before transplantation. For transplantation of ocular tissues, only testing for HIV 1/2, Hepatitis B (Surface Antigen) and Hepatitis C should be required based on a previous evaluation of HTLV 1/2 and VDRL testing in this setting.

1.2 Should there be additional tests used for organ and tissue donors (e.g. CMV)?

Additional serologic tests are required depending on the organ/tissue and patient population (e.g. for CMV – bone marrow transplantation, EBV – paediatric patients, Hepatitis B (Core Antibody) – in liver transplantation, and toxoplasmosis – organs in selected circumstances). Addition of new tests should be based on a scientific assessment of risk. These tests should be mandatory in each area, but the information need not necessarily preclude the use of a specific tissue or organ. The consensus is that the approach should be one of disease detection, and that the standard or guideline should indicate which disease to search for, rather than specify which test to use.

2. Which laboratories should be used for donor testing?

Accredited laboratories should be used for serologic testing. There should be a national defined standard, which doesn't currently exist.

3. What specific serological tests should be carried out to detect disease in donors?

Sera should be stored in the event more effective and efficient tests become available.

3.1 Should specific protocols for testing be required?

Specific protocols (standard operating procedures) should be developed for testing that would define the minimum type/number of tests necessary and ensure that the results of the tests are recorded in the patient’s record.
3.2 If, in the future, new types of tests are introduced for blood donors (e.g. HIV-antigen tests and PCR tests), would there be reasons for not introducing these for the testing of organ and tissue donors?

New tests should be introduced following an evaluation of them in a selected number of Canadian laboratories that test specimens from transplantation programs. These Canadian laboratories should be selected on the basis of the volume of specimens processed.

Unresolved Issues

- evaluation of serologic tests on cadaveric blood and in specimens in which hemodilution has occurred
- need for national accreditation standards for laboratories
- need for a national mechanism to evaluate new tests and/or the use of evaluation by other national (non-Canadian) agencies such as the FDA.
Donor Screening
Chair: Dr. Paul Greig
Rapporteurs: Dr. David Colpitts and Dr. Bill Freeland

Questions 1, 4 and 7 were grouped, as were questions 2, 3 and 5. Questions 6 and 8 were dealt with separately.

Areas of Consensus

1. Should organ and tissue donors be asked the same screening questions for high-risk behaviours and high-risk exposures that are asked when screening blood donors?

Yes. Add genetic issues and occupation. The answer will either be a) yes, b) no, or c) unknown.

4. Should the screening process elements be the same for cadaveric and living donations?

Yes, but acknowledge that living donor information is better.

7. Who is qualified to screen donors?

It is the responsibility of the medical director to decide who is qualified to do donor screening in each region. There should be an established formal training procedure for staff at each centre. Need for confidentiality should be emphasized.

2. Which pre-existing conditions in the donor's history are acceptable and which are not?

A comprehensive medical history should be obtained on each donor. The decision as to the use of any tissue/organ is the responsibility of the transplant physician or the medical director of the tissue bank. He or she would seek lay input to decide which pre-existing conditions in the donor are acceptable.

3. What are the relevant signs that should be noted on physical examination?

Signs of high-risk behaviour (e.g. needle tracks, tattoos, STDs), existing disease (e.g. jaundice, adenopathy) or previous surgery, or review of medical records. Detail of physical examination will depend on the organ or tissue being donated.

5. What other sources of information about the donor may be useful?

Primary source of information is family, including the family doctor. Other sources should be used at the discretion of the health care professional.
Unresolved Issues

6. *Who is responsible for recalling and retesting donors, and for recipient tracking when necessary? How much documentation will this involve and who is responsible for the documentation?*

There is agreement that the medical director is responsible for reporting and initiating tracking after being notified by the responsible physician of an adverse reaction. There is also agreement that each organ procurement organization is responsible for maintaining a tracking mechanism.

Unresolved: voluntary versus mandatory regular reporting and national surveillance – auditing.

8. *Is the draft Canadian General Standard on donor-screening appropriate and adequate?*

Unresolved: duration of storage of donor serum (p. 20 of proposed Canadian General Standard). Query 5 or 10 years storage beyond use of all donated tissue from single source.
Record-Keeping/Labelling and Packaging  
Chair: Ms. Prudence Taylor  
Rapporteur: Mr. Robert Symons  

Areas of Consensus  

1. Can a national registry be established with existing resources?  

Consensus reached was about the need for a national registry for all organ, tissue and cell groups. Registries do exist, but many are fragmented, and there is no national accountability or standards. It was thought that existing resources should be explored as a step towards a national registry, understanding the limitations that currently exist.  

2. What are the requirements of appropriate packaging?  

2.1 What barriers/layers are required to ensure the safety and quality of product?  

2.2 Rigid containers versus bags?  

2.3 What type and quality of material is suitable for packaging the various organs and tissues?  

Standards of packaging need to be developed for each organ, tissue and cell group that will ensure the integrity and sterility of the organ, tissue or cells. The packaging material will be defined by each group and, if possible, meet industry standards for the purposes for which the material is intended.  

3. What are the requirements of appropriate labelling?  

3.1 What information should be on each package?  

3.2 What methods are suitable for labelling?  

Comprehensive, complete and uniform standards of labelling need to be developed for each organ, tissue and cell group. These standards should be adaptable and ensure that testing stored samples can be achieved with emerging technology. The mechanism for labelling should use current technology to provide a permanent record of the donor's identity. New labelling technology must be applied to samples in a way that does not put stored samples at risk.  

A package insert will include such information as deemed critical by each group. Mechanisms must be in place to ensure donor confidentiality and, if possible, anonymity.
3.3 How should shipment containers be labelled?

External containers will be labelled only with exporter and importer identification and contact information. Mechanisms to prevent tampering should be in place.

4. What federal security guidelines will need to be addressed?

Local, provincial and federal regulations should be complied with.

5. What information constitutes basic donor information? Could a standard form be developed for this purpose?

5.1 What information should accompany an organ/tissue to the transplant centre?

The information that constitutes a permanent donor record must be decided upon by each organ, tissue and cell group. All critical donor information will be archived in duplicate to ensure the ability to track and trace outcome.

Note: There seemed to be general agreement on the use of technological labelling (i.e. bar codes) with the assistance/support of the private sector. There were also significant concerns raised about the possibility and ramifications of mislabelled organs/tissues. The importance for standardization and uniformity of labelling was agreed to be critical.
Reporting/Databases

Chair: Dr. Locksley McGann  
Rapporteur: Ms. Pauline Copleston

How should information be recorded (i.e. computerized), and at what level should it be recorded (e.g. unit level, provincial stats, national stats)?

Can there be national agreement on the criteria for tests, procedures and recording standards (i.e. same units, code lists, etc.)?

How could a national registry be established with existing resources?

Areas of Consensus

1. There must be a mechanism to track organs and tissues from the recipient to the donor, and to all other recipients.
2. There must be central reporting of adverse reactions, with reaction times reflecting the urgency of preventing disease transmission.
3. Information must be collected and retained at the centre level to demonstrate compliance with regulations and quality.
4. Data collected must include mandatory donor information and tests; it would be most useful to have a common standard for the format of data.
5. The compliance process should include the mechanism for reporting to the national agency.
6. Centres must have a mechanism for tracking complications.
7. The national agency should maintain a list of who’s transplanting what, and a registry of relevant complications.
8. There are existing databases, and these should be utilized whenever possible.

Unresolved Issues

It was recognized that information is needed at different levels, but the linkages and flow of information between the levels has not been defined.

It was also not defined as to who will take responsibility for which segment of the data-tracking procedure, but general recognition was that the bulk will fall on the actual transplant centres.

Note: General consensus was achieved in plenary that there must be a common format for data storage.
Oversight and Compliance – Plenary Session

The session began with five expert presentations followed by a review of the process with the intention of achieving consensus on the critical issues.

Accreditation Process
Dr. John Jarrell

! The driving force of accreditation must be to facilitate professional-patient interaction.
! The task is to balance accreditation and regulatory requirements.
! The standards have to be exceedingly high because the patients are healthy to begin with, and the technology is one based on "quality of life" issues rather than life-saving issues.
! A third party, such as the CCHSA, is crucial for legitimacy.
! The focus must be on the patient as client.

There is an immense challenge in undertaking a process to respond to the request for patient safety in the field of reproductive technologies. One of the major aspects of reproductive care is the lack of public trust that has been identified by the Royal Commission on New Reproductive Technologies.

Additional environmental factors that are affecting the process of oversight in the field of reproductive tissue transplantation include the absence of standardized guidelines for reproductive technology as well as differing funding mechanisms throughout Canada and a myriad of complex ethical issues.

The presentation focused on a partnership process that has been developed through the Canadian Fertility and Andrology Society, the Society of Obstetricians and Gynaecologists of Canada and the CCHSA. These groups have developed an accreditation process that, it is hoped, will begin to build a return of public trust and standardized care in this very important field of reproductive medicine.

Licensure/Inspection
Dr. Locksley McGann, Dr. Alfonso Del Valle

Dr. Locksley McGann

Organ and tissue transplantation has become routine in many disciplines of clinical medicine, creating an increasing demand for banking services in Canada and elsewhere. As with all clinical services, safety, efficacy, and economy are issues of paramount importance. The organ and tissue-banking community must ensure that safe and effective practices are consistently applied and documented across the country. This requires national standards with mandatory licensing and inspections.
Licensure

This must include all tissues and organs, as well as all sources of those organs and tissues, such as tissues coming into the country from commercial sources, tissues from non-profit sources and tissues recovered in Canada for the purpose of transplantation. All tissues that are designated for transplantation in Canada must fall under the same sets of conditions. These rules must also be consistent across Canada. The first way licensing can be accomplished is by registration, in which the national agency is informed of the activity. The second method is certification, in which the national agency approves of the activity. At the moment, neither system is in place. Many European countries, and Australia, have chosen registration.

Inspections

Inspections should cover all levels of activity, from donor identification to distribution of tissues. The critical issue is safety; however, at some point, the issue of quality must be addressed. Inspections should be performed by a national agency, as opposed to a peer inspection group, because there will have to be a penalty of some sort for non-compliance. The national agency should contract for the expertise it requires for inspections, rather than having all those different areas of expertise itself. The inspections should be periodic (interval to be determined). Should the inspections be announced or unannounced? In the U.S., the FDA is moving towards unannounced inspections, while in most other countries, some period of warning is provided. The rationale is to provide an opportunity for the relevant personnel to be present. It is likely that Canada will choose the "unannounced" route. There must be consequences for non-compliance, which could range from a period of time to meet compliance standards to closure or destruction of current inventory of organs/tissues.

Note: The Bureau of Biologics currently conducts announced and unannounced inspections.

Dr. Alfonso Del Valle

A national regulatory authority in Canada is required to establish and maintain national standards for tissue and organ cryobanks. This regulatory authority should be responsible for the accreditation and licensing of tissue and organ cryobanks. Passing a rigorous inspection of the facilities must be the basis of acquiring accreditation and licensing. Periodic inspection thereafter will ensure compliance with the national standards and, therefore, with accreditation and licensure. Prevention of disease transmission by tissues and organs used for transplantation should always be a major priority when performing an inspection. The inspectors should be selected by the regulatory authority from a group of experts. It is important that the inspector demonstrate knowledge of the tissue-specific issues associated with the tissue or organ cryobank inspected. A tissue-specific inspection allows for a better strategy for the prevention of disease transmission by tissues and organs used for transplantation. The inspection must include the following areas of operations of a cryobank: administration, facilities and equipment, the practices and procedures manual, donor records, and tissue and organ storage, labelling, distribution and tracking.
Administrative inspections should include institutional identity, the mission statement, articles of incorporation and the statement of purpose and scope. A board of trustees, or advisory board, should include lay representatives and persons knowledgeable in the field in which the facility is operating. The hierarchical organization chart of the facility should clearly outline the job descriptions of the key employees, their credentials, and the responsibilities for and delegation of technical work. A critical review of the medical or laboratory director is essential. The integrity of the facility's data, both substantive and physical, must be maintained. The standard operating procedures manual must match the observed behaviour, and that manual must reflect the latest procedures. The existence of an up-to-date file about adverse reactions will give the inspector the assurance that the facility is actively tracking and auditing organs and tissues.

Inspections of facilities and equipment should concentrate on documentation of regularly scheduled maintenance and safety procedures. The facility must comply with occupational safety standards, and be able to demonstrate environmental safety procedures.

Inspections of donor records must involve a review of releases from quarantine, confidentiality, informed consent, quality assurance and control. Accuracy and completeness are essential. Screening practices from the standard operating procedures manual should be obvious in the documentation.

Inspection of the storage facilities should concentrate on the adequacy of inventory control as well as the reliability of the storage equipment.

Labelling should be clear and unambiguous. Tracking mechanisms must be audited, and must be transparent through the entire procedure.

National Standards/Monitoring
Mr. André La Prairie, Dr. Paul Dubord

Mr. André La Prairie

There is currently a plethora (approximately 50) of guidelines and standards for the banking of organs and tissues. Some of these guidelines and standards are organ/tissue-specific, and others are disease-specific. They are produced by a variety of associations and societies and cover all aspects of transplantation: donor-screening, serology-testing, record-keeping and workplace safety.

While all guidelines and standards are recommended, very few have been made mandatory to date. In the U.S., the FDA noted that while the American Association of Tissue Banks published very good standards for tissue-banking and offered inspection and accreditation services, only a very small percentage of tissue banks participated in this process. Solid-organ programs also have seen the need to establish minimum standards as they continue to improve the sharing and allocation of organs between centres. In Europe, Australia and the U.S., tissue banks have been addressing the need for standards, inspection and accreditation as the global market for tissues and other human transplants expands.

The result has been that all countries are now recognizing that the safety of organs and tissues
used for transplantation requires nationally recognized standards, mandatory reporting of transplant activities and an inspection/accreditation process. Moreover, the requirement for an independent or third-party involvement is seen as essential.

*Dr. Paul Dubord*

The central issue for standards is the care of the patient. Safety concerns reflect both the safety and quality of the organs/tissues used in transplantation. Safety also includes the safety of the medical personnel.

The medical standards have to be dynamic, comprehensive, modified to current scientific knowledge and financially realistic. They must be formulated through a medical advisory board with technical and administrative input, as well as public input.
Oversight and Compliance – Discussion
Dr. Keith Bailey, Dr. Wilbert Keon (Co-chairs)

Introduction

Dr. Keith Bailey

It has become apparent that there is a real need and desire to achieve consensus on the issues being discussed. The integrity and openness of the regulatory process is the means for creating the atmosphere that alleviates public fears. We are looking for a regulatory framework that will work for us.

Dr. Wilbert Keon

The Canadian General Standard must include the subsets that pertain to each different category of organ and tissue transplants. (The presentation and ensuing discussion centred on the figure entitled Proposed Risk-management/Regulatory Framework, see figure 1, page 5).

The working assumption is that a set of standards can be agreed upon. So the question then becomes, "Once we have them, what are we going to do with them?" Some of these standards can be enforced by regulation, but not all of them. The ones that cannot be enforced by regulation could be enforced, on a voluntary basis, by an accreditation process. How would one go about an accreditation process? An existing association (e.g. the Canadian Hospital Association) could assist in the process. The regulatory part of the process could be handled by the Bureau of Biologics, Drugs Directorate, which could handle the responsibilities for inspection and audit.

There must also be a registry, or central repository, for tracking, consensus reports, specific donor/recipient information, and complications and adverse reactions. CORR already handles much of this information, and its capacity could be increased to manage the remaining data requirements. There must also be a feedback loop through an expert advisory committee with the capability of assembling experts, such as those present at the conference, as necessary, until the system is functional. The expert advisory committee could "massage" the information it receives, then feed back into the subsets of the Canadian General Standard to filter back through the system.

Dr. Keon posed the following questions to start the discussion:

- What level of risk-management strategy is appropriate?
- Is inspection and/or accreditation needed?
- What is/should be the consequence for non-compliance?
- What is an appropriate risk-management/regulatory option?
Discussion

The discussion raised several points germane to oversight and regulation. It included the regulatory role of the Bureau of Biologics, Drugs Directorate, "third-party" associations, methods of reporting of organ and tissue activity, and methods of recording adverse reactions and complications.

It was agreed that both the use of existing technologies and data, and the networking of all existing organizations would be cost effective.

The participants in the workshop on bone marrow reiterated their position that there is a need for an independent third party responsible for accreditation.

Important to the accreditation process are the inclusion of lay people and the creation of a mechanism to ensure that results are made public. It was suggested that outcome analysis be addressed and that this be dealt with during the implementation process.
Oversight and Compliance – Summary

There is general agreement on the proposed *Canadian General Standard on Safety of Organs and Tissues for Transplantation*. The standard will be a template for the development of subsets of specific standards for individual organ and tissue types.

The Drugs Directorate should facilitate the development of a standard with an expert working group/expert advisory committee. Once developed, assurance of compliance by health professionals can either be monitored by federal regulation and/or the accreditation process.

It was moved by Dr. Calvin Stiller, seconded by Dr. Allan MacDonald, and unanimously carried, that the proposed risk-management/regulatory framework be accepted with the caveat that the expert working group be comprised of those societies and professional bodies that are associated with human tissue/organ transplantation. This group should be brought together to give advice on the science and policy related to the development of guidelines and standards. The proposed *Canadian General Standard on Safety of Organs and Tissues for Transplantation* should be referenced and used as a template for the development and refinement of subsets of specific standards for various organs and tissues. It was strongly recommended that the Drugs Directorate, through the Bureau of Biologics, be charged with the responsibility of carrying out this action.
Closing Remarks

Dr. May Smith

This conference was successful in bringing together a broad range of experts in the field of transplantation and in achieving a consensus. The proposed Canadian General Standard on Safety of Organs and Tissues for Transplantation was accepted in principle, and a risk-management/regulatory framework was proposed.

It has been recommended

! that the proposed Canadian General Standard on Safety of Organs and Tissues for Transplantation be revised to incorporate input from experts at the conference;

! that the revised Canadian General Standard on Safety of Organs and Tissues for Transplantation be accepted as a template for the development of subsets of specific standards for individual organ and tissue types; and

! that the risk-management/regulatory framework (see figure 1, page 5) proposed by the participants at the conference be adopted for implementation by the Drugs Directorate.

The report of the conference will be widely distributed for information and comment. The proposed risk-management/regulatory framework will be carefully reviewed and considered by the Drugs Directorate.
Directory of Organizers and Participants

Organizing Committee

Membership

Dr. May Smith – Organizing Committee chair, Conference Co-chair
Chief, Bacterial Products Division
Bureau of Biologics, Drugs Directorate
Health Protection Branch
Health Canada
Ottawa, Ontario

Mr. David Blaker
Head, Risk Assessment and Management Section
Bureau of Drug Policy and Coordination
Drugs Directorate
Health Protection Branch
Health Canada
Ottawa, Ontario

Dr. William Freeland
Chief, Device Evaluation Division
Bureau of Medical Devices
Laboratory Centre for Disease Control
Health Protection Branch
Health Canada
Ottawa, Ontario

Dr. Paul Gully
Director, Bureau of Communicable Disease Epidemiology
Laboratory Centre for Disease Control
Health Protection Branch
Health Canada
Ottawa, Ontario

Dr. Anthony Ridgway
Head, Biotechnology Section
Blood Products Division
Bureau of Biologics, Drugs Directorate
Health Protection Branch, Health Canada
Ottawa, Ontario

Expert Advisors

Dr. Paul Dubord
Clinical Associate Professor
University of British Columbia
Vancouver, British Columbia

Dr. Paul Greig
Director, G.I. Transplant Program
Toronto Hospital
Toronto, Ontario

Dr. John Jarrell
Senior Operating Officer for Medical Affairs and Research
Tertiary, Academic, Regional Services
Foothills Hospital
Calgary, Alberta

Dr. Wilbert Keon
Director General
Ottawa Heart Institute
Ottawa, Ontario

Mr. André La Prairie
Tissue Bank Specialist
Victoria General Hospital
Halifax, Nova Scotia

Dr. Calvin Stiller
Conference Co-chair
Chief of Transplantation
University Hospital
London, Ontario

Conference Coordination and Report Preparation

Mrs. Colleen Mayo-Pankhurst
President
Mayhurst Consulting Group
Nepean, Ontario
Delegates, Speakers, Resource People and Organizers

Dr. Thomas Arrowsmith-Lowe
Director, Human Tissue Program
U.S. Food and Drug Administration (FDA)
1401 Rockville Pike
Rockville MD
20852

Tel.: (301) 827-0970
Fax: (301) 594-6764
E-mail: arrowsmith@al.cber.fda.gov

Workshop 1: Muscular-Skeletal/Heart Valves/Skin
Workshop 2: Donor Screening

Dr. M.T. Aye
Asst. National Director, Blood Services
The Canadian Red Cross Society
1800 Alta Vista Drive
Ottawa ON
K1G 4J5

Tel.: (613) 739-2220
Fax: (613) 739-2505
E-mail: mtaye@magi.com

Workshop 1: Bone Marrow/Stem Cells
Workshop 2: Serology Testing

Dr. Keith Bailey
Director
Bureau of Biologics, Drugs Directorate
Health Protection Branch
Health Canada
Virus Bldg. (Loc# 002A2)
Tunney's Pasture
Ottawa ON
K1A 0L2

Tel.: (613) 957-8064
Fax: (613) 957-6302

Workshop 1: Reproductive Tissues
Workshop 2: Records/Labelling

Ms. Patty Bakkestad-Legare
Senior Technologist
Canadian Red Cross, Stem Cell Laboratory
226 Osborne St. N.
Canadian Red Cross, BTS
Winnipeg MB
R3N 0R2

Tel.: (204) 982-7431
Fax: (204) 774-2956

Workshop 1: Bone Marrow/Stem Cells
Workshop 2: Records/Labelling

Dr. Norman Barwin
Director
Broadview Fertility/Gynecology Clinic
770 Broadview Ave. Suite B-1
Ottawa ON
K2A 3Z3

Tel.: (613) 728-5108
Fax: (613) 722-6214

Workshop 1: Reproductive Tissues
Workshop 2: Records/Labelling

Mr. Max Bishop
Co-ordinator
Organ Procurement and Exchange of Nfld.
Room 2765A, Health Science Centre
Prince Philip Drive
St. John's NF
A1B 3V6

Tel.: (709) 737-6600
Fax: (709) 737-6400

Workshop 1: Solid Organs
Workshop 2: Donor Screening
Report of the National Consensus Conference
on Safety of Organs and Tissues for Transplantation

Mr. David Blaker
Head, Risk Assessment and Management
Bureau of Drug Policy and Coordination
Drugs Directorate, Health Protection Branch
Health Canada
Room 2012, Jeanne Mance Building
Tunney's Pasture
Ottawa ON
K1A 0L2
Tel.: (613) 941-5057
Fax: (613) 941-6458
E-mail: dblaker@hpb.hwc.ca

Workshop 1: Ocular Tissues
Workshop 2: Reporting/Databases

Dr. Jacques Bourque
Clinical Prof. and Sperm Bank Director (IMRM)
Université de Montréal
1100 Beaumont#305
Mont Royal PQ
H3P 3H5
Tel.: (514) 345-8535
Fax: (514) 345-8978

Workshop 1: Reproductive Tissues
Workshop 2: Reporting/Databases

Dr. Robert F. Casper
Prof. and Head, Division of Repro. Sciences
University of Toronto
6-246 EN, The Toronto Hospital
200 Elizabeth St.
Toronto ON
M5G 2C4
Tel.: (416) 340-3819
Fax: (416) 340-4022
E-mail: r.casper@utoronto.ca

Workshop 1: Reproductive Tissues
Workshop 2: Donor Screening

Mr. David Colpitts
Transplant Co-ordinator
MORE Program
10 NU-116, 200 Elizabeth St.
Toronto ON
M5G 2C4
Tel.: (416) 340-3587
Fax: (416) 340-4539

Workshop 1: Muscular-Skeletal/Heart Valves/Skin
Workshop 2: Donor Screening

Mrs. Marilyn Colton
Assistant Executive Director
Canadian Council on Health Services Accreditation
1730 St. Laurent Blvd., Suite 403
Ottawa ON
K1G 5L1
Tel.: (613) 738-2968
Fax: (613) 738-3755

Workshop 1: Reproductive Tissues
Workshop 2: Reporting/Databases

Ms. Pauline Copleston
Manager, Canadian Organ Replacement Register
Canadian Institute for Health Information
250 Ferrand Dr.
Don Mills ON
M3C 2T9
Tel.: (416) 429-0477
Fax: (416) 429-1953

Workshop 1: Solid Organs
Workshop 2: Reporting/Databases
Dr. Jacques Corman  
Medical Director  
Quebec-Transplant  
155 chemin des Patriotes Sud  
St-Hilaire PQ  
J3H 3G5  
Tel.: (514) 876-6836  
Fax: (514) 464-3769  
Workshop 1: Solid Organs  
Workshop 2: Serology Testing  

Dr. Alfonso Del Valle  
President and Medical Director  
Repromed Ltd.  
56 Aberfoyle Crescent, Suite 209  
Toronto ON  
M8X 2W4  
Tel.: (416) 233-1212  
Fax: (416) 233-8360  
Workshop 1: Reproductive Tissues  
Workshop 2: Records/Labelling/Packaging  

Dr. William Dixon  
Medical Director  
Eye Bank of Canada  
Suite A 233-2075 Bayview Ave.  
Toronto ON  
M4N 3M5  
Tel.: (416) 487-9100  
Fax: (416) 480-4481  
Workshop 1: Ocular Tissues  
Workshop 2: Donor Screening  

Dr. Paul J. Dubord  
Clinical Associate Professor  
University of British Columbia  
#1603-805 West Broadway  
Vancouver BC  
V5Z 1K1  
Tel.: (604) 879-9144  
Fax: (604) 879-9154  
Workshop 1: Ocular Tissues  
Workshop 2: Serology Testing  

Dr. Allen Eaves  
Head, Hematology  
University of British Columbia  
Terry Fox Laboratory  
601 West 10th Ave.  
Vancouver BC  
V5Z 1L3  
Tel.: (604) 877-6070  
Fax: (604) 877-0712  
Workshop 1: Bone Marrow/Stem Cells  
Workshop 2: Reporting/Databases  

Dr. Marilyn Ekins  
Medical Director  
Lions Eye Bank of Manitoba and N.W. Ontario  
425 St. Mary Avenue  
Winnipeg MB  
R3C 0N2  
Tel.: (204) 957-3251  
Fax: (204) 943-2164  
Workshop 1: Ocular Tissues  
Workshop 2: Records/Labelling/Packaging
Report of the National Consensus Conference
on Safety of Organs and Tissues for Transplantation

Dr. Margaret Fearon
Chief Virologist
Ontario Ministry of Health
Laboratory Services Branch
81 Resources Road
Etobicoke ON
M9P 3T1
Tel.: (416) 235-5726
Fax: (416) 235-6197

Workshop 1: Bone Marrow/Stem Cells
Workshop 2: Serology Testing

Mr. Raffaele Forcione
Director of Co-ordination Services
Quebec-Transplant
4200 boul., St. Laurent, Suite 1111
Montreal PQ
H2W 2R2
Tel.: (514) 286-1414
Fax: (514) 286-0615

Workshop 1: Muscular-Skeletal/Heart Valves/Skin
Workshop 2: Records/Labelling/Packaging

Dr. William Freeland
Chief, Device Evaluation Division
Laboratory Centre for Disease Control
Health Protection Branch, Health Canada
Room 1605, Main Statistics Bldg.
Tunney's Pasture (Loc# 0301H1)
Ottawa ON
K1A 0L2
Tel.: (613) 954-0298
Fax: (613) 941-4726

Workshop 1: Muscular-Skeletal/Heart Valves/Skin
Workshop 2: Donor Screening

Dr. Antonio Giulivi
Medical Director
Canadian Red Cross
85 Plymouth St.
Ottawa ON
K1S 3E2
Tel.: (613) 560-7204
Fax: (613) 560-7226

Workshop 1: Bone Marrow/Stem Cells
Workshop 2: Serology Testing

Ms. Carol Goldman
Infection Control Practitioner
CHICA-Canada
600 University Ave. Room 1460
Toronto ON
M5G 1X5
Tel.: (416) 586-4570
Fax: (416) 586-3140
E-mail: 102620.561@compuserve.com

Workshop 1: Solid Organs
Workshop 2: Donor Screening

Dr. Paul Greig
Director, G.I. Transplantation
University of Toronto
NU10-152, 200 Elizabeth St.
Toronto General Hospital
Toronto ON
M5G 2C4
Tel.: (416) 340-4252
Fax: (416) 340-3492

Workshop 1: Solid Organs
Workshop 2: Donor Screening
Report of the National Consensus Conference on Safety of Organs and Tissues for Transplantation

Dr. Michael Gross
Associate Professor, Dalhousie University
Suite 4135 ACC.
Victoria General Hospital
Halifax NS
B3H 2Y9
Tel.: (902) 428-3811
Fax: (902) 428-2042
Workshop 1: Muscular-Skeletal/Heart Valves/Skin
Workshop 2: Donor Screening

Dr. David Howarth
Medical Director, Staff Pathologist
Rachel and David Rubinoff Bone and Tissue Bank
Mount Sinai Hospital
600 University Ave., Rm.600-10
Toronto ON
M5G 1X5
Tel.: (416) 586-4670
Fax: (416) 586-8628

Workshop 1: Muscular-Skeletal/Heart Valves/Skin
Workshop 2: Serology Testing

Dr. Paul R. Gully
Chief, Div. of Blood-Borne Pathogens
Laboratory Centre for Disease Control
Health Protection Branch
Health Canada
Rm. 1704, Jeanne Mance Bldg.
Tunney's Pasture
Ottawa ON
K1A 0K9
Tel.: (613) 957-1789
Fax: (613) 952-6668

Dr. John Jarrell
Senior Medical Officer, Acute Care Section
Calgary Regional Health Authority
Foothills Hospital
1403-29 St. N.W.
Calgary AB
T2N 2T9
Tel.: (403) 670-1403
Fax: (403) 670-1044
E-mail: jarrell@acs.ucalgary.ca

Workshop 1: Reproductive Tissues
Workshop 2: Records/Labelling/Packaging

Dr. Jeremy P.W. Heaton
Department of Urology
Kingston General Hospital
76 Stuart St.
Kingston ON
K7L 2V7
Tel.: (613) 545-1971
Fax: (613) 545-1970
E-mail: heatonj@qucdn.queensu.ca

Dr. John Jeffery
Head, Section of Nephrology
University of Manitoba
E441-Health Sciences Centre
Winnipeg MB
R3A 1R9
Tel.: (204) 787-7001
Fax: (204) 787-3040
E-mail: john_jeffrey@umanitoba.ca

Workshop 1: Muscular-Skeletal/Heart Valves/Skin
Workshop 2: Reporting/Databases
### Dr. Armand Keating
**Director, Autologous Blood and Marrow Transplant**
The Toronto Hospital  
200 Elizabeth St.  
ML 2-036  
Toronto ON  
M5G 2C4  
Tel.: (416) 340-3993  
Fax: (416) 340-5087

**Workshop 1:** Bone Marrow/Stem Cells  
**Workshop 2:** Serology Testing

### Dr. Wilbert J. Keon
**Director General**
Ottawa Heart Institute  
1053 Carling Avenue  
Ottawa ON  
K1Y 4E9  
Tel.: (613) 761-4779  
Fax: (613) 761-5323

**Workshop 1:** Solid Organs

### Dr. Robert Kinch
**Associate Executive Vice President**
Society of Obstetricians and Gynaecologists  
774 Echo Drive  
Ottawa ON  
K1S 5N5  
Tel.: (613) 730-4192  
Fax: (613) 730-4314

**Workshop 1:** Reproductive Tissues  
**Workshop 2:** Reporting/Databases

### Dr. Norman Kneteman
**President**
Canadian Transplantation Society  
Dept. of Surgery, 2D4.43  
Mackenzie Centre, University of Alberta  
Edmonton AB  
T6G 2B7  
Tel.: (403) 492-4062  
Fax: (403) 492-4923

**Workshop 1:** Muscular-Skeletal/Heart Valves/Skin  
**Workshop 2:** Serology Testing

### Dr. Jonathan Kronick
**Associate Professor of Paediatrics**
University of Western Ontario  
Children's Hospital of Western Ontario  
800 Commissioner Rd. E.  
London ON  
N6C 2V5  
Tel.: (519) 685-8132  
Fax: (519) 685-8156

**Workshop 1:** Solid Organs  
**Workshop 2:** Donor Screening

### Mr. André La Prairie
**Senior Tissue Bank Specialist**
Regional Tissue Bank  
Victoria General Hospital  
Halifax NS  
B3J 2Y9  
Tel.: (902) 428-4171  
Fax: (902) 428-2042  
E-mail: Andre_La_Prairie@isdtcp3.hwc.ca

**Workshop 1:** Ocular Tissues  
**Workshop 2:** Records/Labelling
Dr. Arthur Leader  
Prof. and Chief, Div. of Repro. Endocrinology  
University of Ottawa  
Suite 510, Parkdale Clinic  
Ottawa Civic Hospital  
1053 Carling Ave.  
Ottawa ON  
K1Y 4E5  
Tel.: (613) 761-4427  
Fax: (613) 724-4942  
Workshop 1: Reproductive Tissues  
Workshop 2: Reporting/Databases

Dr. André-Marie Leroux  
Medical Officer  
Bureau of Human Prescription Drugs  
Drugs Directorate  
Health Protection Branch, Health Canada  
Holland Cross, 1600 Scott St.  
Ottawa ON  
K1A 1B8  
Tel.: (613) 941-3173  
Fax: (613) 941-1365  
Workshop 1: Reproductive Tissues  
Workshop 2: Records/Labelling/Packaging

Dr. David Ludwin  
Professor, Associate Dean (Research)  
 McMaster University  
Dept. of Medicine, St. Joseph's Hospital  
50 Charlton Ave. E.  
Hamilton ON  
L8N 4A6  
Tel.: (905) 521-6049  
Fax: (905) 521-6088  
E-mail: ludwin@fhs.mcmaster.ca  
Workshop 1: Solid Organs  
Workshop 2: Reporting/Databases

Dr. Allan S. MacDonald  
Prof. and Transplant Director  
Dept. of Surgery  
Multi-Organ Transplant Program  
ACC 4134  
Victoria General Hospital  
Halifax NS  
B3H 2Y9  
Tel.: (902) 428-2532  
Fax: (902) 428-4426  
Workshop 1: Solid Organs  
Workshop 2: Donor Screening

Dr. Noni MacDonald  
Chief of Infectious Disease  
Children's Hospital of Eastern Ontario  
401 Smyth Rd.  
Ottawa ON  
K1H 8L1  
Tel.: (613) 737-2651  
Fax: (613) 738-4832  
Workshop 1: Bone Marrow/Stem Cells  
Workshop 2: Donor Screening

Dr. Locksley McGann  
Prof., Director, Comprehensive Tissue Centre  
University of Alberta  
Red Cross Building  
Edmonton AB  
T6G 2R8  
Tel.: (403) 431-0202  
Fax: (403) 431-0461  
E-mail: locksley.mcgann@ualberta.ca  
Workshop 1: Muscular-Skeletal/Heart Valves/Skin  
Workshop 2: Reporting/Databases
Report of the National Consensus Conference  
on Safety of Organs and Tissues for Transplantation

Dr. Hans Messner  
Director, Bone Marrow Transplant  
Princess Margaret Hospital  
610 University Ave.  
Toronto ON  
M5G 2M9  
Tel.: (416) 946-2266  
Fax: (416) 926-6585

Workshop 1: Bone Marrow/Stem Cells  
Workshop 2: Donor Screening

Mr. Dann Michols  
Director General  
Drugs Directorate  
Health Protection Branch  
Health Canada  
HP Bldg#7  
Tunney's Pasture (Loc#0702A)  
Ottawa ON  
K1A 0L2  
Tel.: (613) 957-0369  
Fax: (613) 952-7756  
E-mail: Dann_Michols@isdtcp3.hwc.ca

Opening Remarks

Ms. Alison Murchie  
Manager, Information Systems  
MORE Program of Ontario  
984 Bay St. Suite 503  
Toronto ON  
M5S 2A5  
Tel.: (416) 921-1130  
Fax: (416) 921-7313

Workshop 1: Solid Organs  
Workshop 2: Records/Labelling/Packaging

Dr. Lindsay Nicolle  
Director, Infectious Control Unit  
Health Sciences Centre  
MS-675 D  
820 Sherbrook St.  
Winnipeg MB  
R3A 1R9  
Tel.: (204) 787-4655  
Fax: (204) 787-4699

Workshop 1: Muscular-Skeletal/Heart Valves/Skin  
Workshop 2: Reporting/Databases/Packaging

Dr. Mark K. Nigro  
Director of Organ Retrieval  
British Columbia Transplant Society  
6115 St. Clair Place  
Vancouver BC  
V6N 2A6  
Tel.: (604) 875-5683  
Fax: (604) 875-5604  
E-mail: nigro@unixg.ubc.ca

Workshop 1: Solid Organs  
Workshop 2: Donor Screening

Dr. Anthony Ridgway  
Head, Biotechnology Section  
Bureau of Biologics, Drugs Directorate  
Health Protection Branch  
Health Canada  
Bldg#7  
Tunney's Pasture (Loc# 0700C3)  
Ottawa ON  
K1A 0L2  
Tel.: (613) 952-3605  
Fax: (613) 954-4514

Workshop 1: Bone Marrow/Stem Cells  
Workshop 2: Serology Testing
Report of the National Consensus Conference
on Safety of Organs and Tissues for Transplantation

Dr. Gail Rock
Chairman
Canadian Apheresis Group
206-435 St. Laurent Blvd.
Ottawa ON
K1K 2Z8
Tel.: (613) 748-9613
Fax: (613) 748-6392
Workshop 1: Bone Marrow/Stem Cells
Workshop 2: Serology Testing

Dr. Walter Schlech
Professor of Medicine
Dalhousie University
ACC 5014
Victoria General Hospital
Halifax NS
B3H 2Y9
Tel.: (902) 428-3742
Fax: (902) 428-2023
E-mail: wfsiii@ac.dal.ca
Workshop 1: Reproductive Tissues
Workshop 2: Donor Screening

Mrs Heather Sherrard
Director of Nursing
University of Ottawa Heart Institute
1053, av. Carling, bureau H205
Ottawa Hospital Civic
Ottawa ON
K1Y 4E9
Tel.: (613) 761-4826
Fax: (613) 761-5323
Workshop 1: Muscular-Skeletal/Heart Valves/Skin
Workshop 2: Records/Labelling/Packaging

Dr. Marilyn Schneider
Administrator
Eye Bank of Canada (Ontario Division)
1 Spadina Crescent, Room 114
Toronto ON
M5S 2J5
Tel.: (416) 978-2637
Fax: (416) 978-1522
Workshop 1: Ocular Tissues
Workshop 2: Donor Screening

Dr. Ahmed Shoker
Head of Nephrology
Royal University Hospital
103 Hospital Drive
Saskatoon SK
S7N 0W8
Tel.: (306) 966-7985
Fax: (306) 966-8021
Workshop 1: Solid Organs
Workshop 2: Serology Testing

Dr May Smith
Chief, Blood and Tissues Division
Bureau of Biologics, Drugs Directorate
Health Protection Branch
Health Canada
LCDC Bldg.#6
Tunney's Pasture (Loc# 0603C3)
Ottawa ON
K1A 0L2
Tel.: (613) 952-0237
Fax: (613) 941-5841
Report of the National Consensus Conference on Safety of Organs and Tissues for Transplantation

Dr. Werner Specht
Managing Director
Biodynamics International
Wetterkreuz 19a
D-91058
Erlangen
GERMANY
Tel.: (913) 179-0110
Fax: (913) 179-0112

Workshop 1: Ocular Tissues
Workshop 2: Serology Testing

Dr John Spika
Director, Bureau of Communicative Disease Epidemiology
Laboratory Centre for Disease Control
Health Protection Branch
Health Canada
Tunney's Pasture
Ottawa ON
K1A 0L2
Tel.: (613) 957-4243
Fax: (613) 998-6413
E-mail: jspika@hpb.hwc.ca

Workshop 1: Ocular Tissues
Workshop 2: Serology Testing

Dr. Calvin Stiller
Chief, Transplantation
University Hospital
Multi-Organ Transplant Service
339 Windermere Rd.
London ON
N6A 5A5
Tel.: (519) 663-3352
Fax: (519) 663-3858
E-mail: cstiller@julian.uwo.ca

Workshop 1: Solid Organs

Mr. Robert Symons
Transplant Donor Co-ordinator
University Hospital
Multi-Organ Transplant Service
339 Windermere Rd., 4TU60
London ON
N6A 5A5
Tel.: (519) 663-3060
Fax: (519) 663-3966

Workshop 1: Solid Organs
Workshop 2: Records/Labelling/Packaging

Mrs. Prudence Taylor
Program Manager, Transplant Services
Capital Health Authority: Edmonton
8440-112th Street
Edmonton AB
T6G 2B7
Tel.: (403) 492-8453
Fax: (403) 492-9294

Workshop 1: Muscular-Skeletal/Heart Valves/Skin
Workshop 2: Records/Labelling/Packaging

Dr. Huibert Tjabbes
Deputy Director, Medical Affairs
BIS Foundation
P.O. Box 2304
Leiden 2301
NETHERLANDS
Tel.: (317) 179-5710
Fax: (317) 179-0903

Workshop 1: Muscular-Skeletal/Heart Valves/Skin
Workshop 2: Donor Screening
Report of the National Consensus Conference
on Safety of Organs and Tissues for Transplantation

Dr. Evelyn Wallace
Senior Medical Consultant
Public Health Branch, Ontario Ministry of Health
5700 Yonge St., 8th Floor
North York ON
M2M 4K5
Tel.: (416) 327-7433
Fax: (416) 327-7438
Workshop 1: Bone Marrow/Stem Cells
Workshop 2: Reporting/Database/Packaging

Mrs. Gail Werner
Past President
Canadian Association of Transplantation
HOPE Program
1403 29th Street N.W.
Calgary AB
T2N 2T9
Tel.: (403) 283-2243
Fax: (403) 270-3783
Workshop 1: Solid Organs
Workshop 2: Donor Screening

Mr. Paul Wirtz
Tissue Bank Specialist
BC Tissue Bank
855 W. 12th Ave.
Vancouver BC
V5Z 1M9
Tel.: (604) 875-4692
Fax: (604) 875-4025
Workshop 1: Muscular-Skeletal/Heart Valves/Skin
Workshop 2: Records/Labelling/Packaging

Ms. Carolyn Woodruff
GMP Auditor
Therapeutic Goods Administration of Australia
P.O. Box 9848
Melbourne, Victoria 3150
AUSTRALIA
Tel.: (61)-3-92-858-578
Fax: (61)-3-92-858-979
Workshop 1: Ocular Tissues
Workshop 2: Reporting/Databases

Dr. Albert Yuzpe
Co-Director
Genesis Fertility Centre
Suite 550, 555 West 12th Ave.
Vancouver BC
V5Z 3X7
Tel.: (604) 879-3032
Fax: (604) 875-1432
Workshop 1: Reproductive Tissues
Workshop 2: Records/Labelling/Packaging

Logistics Coordinators and Secretariat

Mrs Linda Ladouceur
Liaison et Co-ordination
Bureau of Drug Policy and Coordination
Drugs Directorate
Health Protection Branch
Health Canada
Room 2008, Jeanne-Mance Bldg.
Tunney's Pasture (Loc# 0702A2)
Ottawa ON
K1A 0K9
Tel.: (613) 941-5174
Fax: (613) 941-1812
Report of the National Consensus Conference
on Safety of Organs and Tissues for Transplantation

Mrs Francine Latremouille
Secretary, Bureau Biologics
Drugs Directorate
Health Protection Branch
Health Canada
LCDC Bldg.#6
Tunney's Pasture (Loc# 0700E)
Ottawa ON
K1A 0L2
Tel.: (613) 952-8318
Fax: (613) 941-5841

Mrs Colleen Mayo-Pankhurst
President
Mayhurst Consulting Group
34, av. Beaverton
Nepean ON
K2E 5K4
Tel.: (613) 224-6307
Fax: (613) 723-0453

Mrs Tanis Nepinak
Logistics Co-ordinator
Mayhurst Consulting Group
34, av. Beaverton
Nepean ON
K2E 5K4
Tel.: (613) 224-6307
Fax: (613) 723-0453

Mrs Ginette Pitre
Chief, Conference and Meeting Services
Health Protection Branch
Health Canada
2202-A Banting Bldg.
Tunney's Pasture (Loc# 2202A)
Ottawa ON
K1A 0L2
Tel.: (613) 957-1899
Fax: (613) 957-1907

Mr. Edan Puritt
Writer/Event Manager
Mayhurst Consulting Group
c/o Info. Age Inc.
10450 Stanley Avenue
Niagara Falls ON
L2E 6S6
Tel.: (905) 295-7937
Fax: (905) 295-6920
E-mail: 70451.3702@compuserve.com

Observers

Dr Phyllis Colvin
Director, Health Policy Division
Health Policy Information Directorate
Policy and Consultation Branch
Health Canada
Room 1029B, Brooke-Claxton Bldg.
Tunney's Pasture (Loc# 0910B)
Ottawa ON
K1A 0K9
Tel.: (613) 957-3085
Fax: (613) 957-1204

Dr Brian Foster
Research Scientist
Bureau of Drug Research
Drugs Directorate
Health Protection Branch
Banting Bldg. #22
Health Canada
Tunney's Pasture (Loc# 2201C)
Ottawa ON
K1A 0L2
Tel.: (613) 957-3506
Fax: (613) 941-8933
E-mail: bfoster@hpb.hwc.ca